Fundamental and clinical studies on cefmenoxime (SCE-1365) in urinary tract infection

Abstract

Cefmenoxime (CMX, SCE-1365) is one of the newly synthesized cephalosporins developed at Takeda Chemical Industries. The drug showed surprisingly strong antibacterial activity against Escherichia coli, Serratia marcescens and Proteus vulgaris. Susceptibility of the drug against Pseudomonas aeruginosa seems to be as same as that of sulbenicillin. Peak serum level reached to 64 μg/ml and 113μg/ml respectively 5 minutes after intravenous administration of 0.5 g and 1.0 g of the drug. The urinary concentration of the drug in the first two hours recorded as high as 1,453 μg/ml and 2,958 μg/ml after the administration. respectively and urinary recovery rate of the drug up to six hours just exceeded 70%. The drug with 1 and 2 grams per day for 5 days was given to 32 cases with chronic complicated urinary tract infections. According to the criterion recommended by Japanese UTI Committee (2nd report), the result showed excellent in 7 cases, moderate in 19 cases and poor in 6 cases. Then overall clinical effectiveness rate becomes 81.3%. No adverse subjective side effects have been noticed except a case who complained of transient nausea. No abnormal data were obtained in blood counts and blood chemistry after the administration of the drug. © 1981, Japanese Society of Chemotherapy. All rights reserved.